Frequency and number of neuroendocrine tumor cells in prostate cancer: No difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy

Neuroendocrine tumor cells in prostate cancer are thought to increase after hormonal therapy due to neuroendocrine differentiation of tumor cells. This assumption is based on the histological analyses of limited portions of the cancerous lesions examined.

[1]  C. Belka,et al.  Secondary hormonal manipulation. , 2008, Frontiers of radiation therapy and oncology.

[2]  R. Grobholz,et al.  Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma , 2006, The Prostate.

[3]  K. Akakura,et al.  Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. , 2005, European urology.

[4]  T. Terachi,et al.  Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer. , 2005, Oncology reports.

[5]  R. Grobholz,et al.  Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. , 2005, Human pathology.

[6]  N. Nemoto,et al.  Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. , 2004, European urology.

[7]  L. Dogliotti,et al.  Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients , 2001, The Prostate.

[8]  S. Lakhani,et al.  Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression. , 1999, Cancer research.

[9]  P. A. Sant'agnese,et al.  Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects , 1998 .

[10]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[11]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic malignancy , 1996, Cancer.

[12]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts , 1995 .

[13]  Y. Bang,et al.  Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. , 1992 .

[15]  F. Labrie,et al.  Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. , 1992, Urology.